This inventor holds 5 USPTO granted patents, plus 2 CIPO patents and 2 EPO patents. Top assignee: Hanmi Science Co., Ltd.. Active years: 2015-2021.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2015-2021
Title: Mi Ji Lee: Innovator in Polypeptide Complexes
Introduction
Mi Ji Lee is a prominent inventor based in Incheon, South Korea. He has made significant contributions to the field of biochemistry, particularly in the development of innovative protein complexes. With a total of five patents to his name, Lee's work focuses on enhancing the stability and efficacy of physiologically active polypeptides.
Latest Patents
One of Mi Ji Lee's latest patents involves a polypeptide complex comprising a non-peptidyl polymer with three functional ends. This innovative protein complex includes a physiologically active polypeptide, a dimeric protein, and a 3-arm non-peptidyl polymer. The unique design allows for the covalent bonding of both the physiologically active polypeptide and the dimeric protein to the polymer. This complex ensures long-acting activity and biostability of the polypeptide, significantly improving its serum half-life. The application of this technology can lead to the development of sustained release formulations for various physiologically active polypeptide drugs. Additionally, it utilizes raw materials efficiently, increasing production yield while allowing for easy purification.
Career Highlights
Mi Ji Lee is currently associated with Hanmi Science Co., Ltd., where he continues to push the boundaries of biopharmaceutical research. His work has garnered attention for its potential applications in drug development and therapeutic solutions.
Collaborations
Lee collaborates with notable colleagues, including Se Chang Kwon and Dae Hae Song, who contribute to the advancement of their shared research goals.
Conclusion
Mi Ji Lee's innovative work in polypeptide complexes showcases his commitment to enhancing drug efficacy and stability. His contributions are paving the way for future advancements in biopharmaceuticals.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile